SHARE:  
Join Our Email List
Insights from Ron
June 2022
Always Advance
Keep pushing the bar higher in your biomedical research. Be open to the unexpected. And don't get spooked by research setbacks or by this year's big pharma investment market dive.
Funding the Unexpected

The U.S. National Institutes of Health is perennially underfunded for foundational research to find treatments for major diseases. Many of the most revolutionary advances in medicine came about through unexpected observations. Without adequate funding, such serendipitous insights are less likely.
Time to Invest
Even in this market meltdown, seasoned biotech innovators with decades of experience know that strong novel science in the hands of experienced teams will eventually succeed.
Research: APC-Resistant Cancers
Using a novel analytic method, termed synthetic essentiality (SE), we identified Tryptophan 2,3-dioxygenase 2 (TDO2) as a SE gene for APC deficient cancers (i.e., TDO2 is a critical downstream effector of APC deficiency). This finding may provide a basis for the costly failures of IDO1 inhibitors in cancer trials and illuminate an alternative strategy for the use of TDO2 inhibitors.
Let's Connect